Echinococcus multilocularis in Canada and the USA: recent developments?

Presented by Andrew S. Peregrine, BVMS, PhD, DVM, Dipl. EVPC, Dipl. ACVM (Parasitology Specialty)

Continuing education questionnaire

CE credit: 1

Nom

Questions

1. Dogs develop intestinal infections with Echinococcus multilocularis by ingesting: *
2. If dogs cannot tolerate albendazole for medical management of alveolar echinococcosis, an alternative efficacious drug is: *
3. The clinical incubation period for alveolar echinococcosis in people is typically: *
4. Human cases of alveolar echinococcosis in North America are currently being most commonly diagnosed in: *
5. True or False. Alveolar echinococcosis in dogs has a unique gross morphological appearance. *
6. The risk of an E. multilocularis intestinal infection is greatest for dogs in: *
7. The public health concern associated with shedding of E. multilocularis eggs in the feces of dogs can be prevented by monthly treatment with: *
8. In North America, resistance to praziquantel has been described in: *
9. The risk of alveolar echinococcosis in dogs can be prevented by monthly treatment with: *
10. In which Canadian province is E. multilocularis in dogs reportable? *